Abstract
Background
ABO blood type antigens are expressed not only on human red blood cells, but also throughout the gastrointestinal tract and in normal pancreatic tissue. Previous studies have identified an association between ABO blood type and various malignancies. We analyzed the association of ABO blood type with pancreatic neuroendocrine tumors (PNETs) in a high-risk cohort of patients with Von Hippel–Lindau (VHL) syndrome.
Methods
A retrospective review was performed of 798 patients with VHL syndrome. Blood type was confirmed for 181 patients. Fisher’s exact test and Mehta’s modification to Fisher’s exact test were used to test for an association between ABO blood type and manifestations of VHL syndrome.
Results
We found a strong trend for association between O blood type and pancreatic disease manifestation in patients with VHL syndrome (P = 0.047). More importantly, there was a significant association of O blood type with solid pancreatic lesions consistent with PNETs (P = 0.0084). Patients with solid pancreatic lesions who met criteria for surgical resection at the National Institutes of Health also had a higher rate of O blood type than those who did not require surgery (P = 0.051).
Conclusions
Our findings suggest an association between O blood type and pancreatic manifestation of disease in patients with VHL syndrome, especially for PNETs. Screening and surveillance approaches for pancreatic lesions in patients with VHL syndrome should also consider patient blood type. The possibility of A, B, H misexpression in PNETs should also be explored to determine whether the serologic association with disease translates into a relationship with tissue pathology.
Similar content being viewed by others
References
Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009;101:424–31.
Greer JB, Yazer MH, Raval JS, Barmada MM, Brand RE, Whitcomb DC. Significant association between ABO blood group and pancreatic cancer. World J Gastroenterol. 2010;16:5588–91.
Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB. ABO blood group and cancer. Eur J Cancer. 2010;46:3345–50.
Nakao M, Matsuo K, Hosono S, et al. ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Cancer Sci. 2011;102:1076–80.
Vioque J, Walker AM. [Pancreatic cancer and ABO blood types: a study of cases and controls]. Med Clin (Barc). 1991;96:761–4.
Wolpin BM, Kraft P, Xu M, et al. Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2010;19:3140–9.
Itzkowitz SH, Yuan M, Ferrell LD, et al. Cancer-associated alterations of blood group antigen expression in the human pancreas. J Natl Cancer Inst. 1987;79:425–34.
Pour PM, Tempero MM, Takasaki H, et al. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient’s blood group type. Cancer Res. 1988;48:5422–6.
Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.
Lonser RR, Glenn GM, Walther M, et al. Von Hippel–Lindau disease. Lancet. 2003;361:2059–67.
Kim JJ, Rini BI, Hansel DE. Von Hippel Lindau syndrome. Adv Exp Med Biol. 2010;685:228–49.
Marcos HB, Libutti SK, Alexander HR, et al. Neuroendocrine tumors of the pancreas in von Hippel–Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology. 2002;225:751–8.
Kitano M, Millo C, Rahbari R, et al. Comparison of 6-(18)F-Fluoro-l-DOPA, (18)F-2-deoxy-d-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel–Lindau disease. Surgery. 2011;150:1122–8.
Libutti SK, Choyke PL, Bartlett DL, et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery. 1998;124:1153–9.
Kayser K, Bovin NV, Korchagina EY, Zeilinger C, Zeng FY, Gabius HJ. Correlation of expression of binding sites for synthetic blood group A-, B- and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma. Eur J Cancer. 1994;30A:653–7.
Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Clement M. ABH and Lewis histo-blood group antigens in cancer. APMIS. 2001;109:9–31.
Matsumoto H, Muramatsu H, Shimotakahara T, et al. Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas. Cancer. 1993;72:75–81.
Nakagoe T, Nanashima A, Sawai T, et al. Expression of blood group antigens A, B and H in carcinoma tissue correlates with a poor prognosis for colorectal cancer patients. J Cancer Res Clin Oncol. 2000;126:375–82.
Yuan M, Itzkowitz SH, Palekar A, et al. Distribution of blood group antigens A, B, H, Lewis A, and Lewis B in human normal, fetal, and malignant colonic tissue. Cancer Res. 1985;45:4499–511.
Melzer D, Perry JR, Hernandez D, et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet. 2008;4:e1000072.
Pare G, Chasman DI, Kellogg M, et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet. 2008;4:e1000118.
Jaff MS. Higher frequency of secretor phenotype in O blood group—its benefits in prevention and/or treatment of some diseases. Int J Nanomed. 2010;5:901–5.
Fujitani N, Liu Y, Toda S, Shirouzu K, Okamura T, Kimura H. Expression of H type 1 antigen of ABO histo-blood group in normal colon and aberrant expressions of H type 2 and H type 3/4 antigens in colon cancer. Glycoconj J. 2000;17:331–8.
Hallouin F, Goupille C, Bureau V, Meflah K, Le Pendu J. Increased tumorigenicity of rat colon carcinoma cells after alpha1,2-fucosyltransferase FTA anti-sense cDNA transfection. Int J Cancer. 1999;80:606–11.
Hazra A, Kraft P, Lazarus R, et al. Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hum Mol Genet. 2009;18:4677–87.
Mas E, Pasqualini E, Caillol N, et al. Fucosyltransferase activities in human pancreatic tissue: comparative study between cancer tissues and established tumoral cell lines. Glycobiology. 1998;8:605–13.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weisbrod, A.B., Liewehr, D.J., Steinberg, S.M. et al. Association of Type O Blood with Pancreatic Neuroendocrine Tumors in Von Hippel–Lindau Syndrome. Ann Surg Oncol 19, 2054–2059 (2012). https://doi.org/10.1245/s10434-012-2276-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-012-2276-8